RxDoctor Payments DataLook up a doctor →

Michael Hornbecker, MD

Internal Medicine · Lebanon, INNPI 1619138096

Payments from drug & device makers

$29,018in general payments, 2019–2025

Across 732 payments — averaging $39.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$7K
  • Eisai Inc.$6K
  • Eli Lilly$6K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Amgen$976
  • plus $7K from 42 others

What the payments were for

  • Consulting fees$15,26353%
  • Travel & lodging$2,1337%
  • Food & beverage$11,43939%
  • Education$1851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,018 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$115,498
Medicare patients
293
Services billed
4,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin157$141,767
OzempicSemaglutide113$140,736
MounjaroTirzepatide136$140,514
EliquisApixaban113$121,962
TrulicityDulaglutide65$82,286
Victoza 3-PakLiraglutide31$38,918
XareltoRivaroxaban59$37,791
JanuviaSitagliptin Phosphate42$37,266
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$28,581
VascepaIcosapent Ethyl69$26,314
FarxigaDapagliflozin Propanediol31$23,714
Tresiba Flextouch U-100Insulin Degludec33$18,241
GlyxambiEmpagliflozin/Linagliptin18$17,314
LinzessLinaclotide24$14,951
MyrbetriqMirabegron17$12,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,116$222,800201 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$314$166,753188 claims
Novo NordiskOzempic$7,247$140,736113 claims
PfizerEliquis$699$121,962113 claims
MerckJanuvia, Janumet$311$44,43355 claims
Johnson & JohnsonXarelto$629$37,79159 claims
GSKTrelegy Ellipta$568$28,58139 claims
AstraZenecaFarxiga$891$23,71431 claims
AbbVieLinzess, Synthroid$1,050$18,96273 claims
Astellas Pharma US IncMyrbetriq$314$12,08817 claims
Sumitomo Pharma America, Inc.Gemtesa$119$9,78012 claims
Sanofi-aventis U.S. LLCLantus$293$5,66626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Lebanon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →